Tumori (TUMORI)

Publisher: Istituto Nazionale per lo Studio e la Cura dei Tumori (Milano)

Journal description

Current impact factor: 1.27

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 1.269
2013 Impact Factor 1.09
2012 Impact Factor 0.922
2011 Impact Factor 0.606
2010 Impact Factor 1.014
2009 Impact Factor 0.863
2008 Impact Factor 0.791
2007 Impact Factor 0.597
2006 Impact Factor 0.701
2005 Impact Factor 0.739
2004 Impact Factor 0.631
2003 Impact Factor 0.348
2002 Impact Factor 0.267
2001 Impact Factor 0.49
2000 Impact Factor 0.485
1999 Impact Factor 0.569
1998 Impact Factor 0.595
1997 Impact Factor 0.408
1996 Impact Factor 0.446
1995 Impact Factor 0.36
1994 Impact Factor 0.352
1993 Impact Factor 0.324
1992 Impact Factor 0.453

Impact factor over time

Impact factor

Additional details

5-year impact 1.12
Cited half-life 7.00
Immediacy index 0.11
Eigenfactor 0.00
Article influence 0.30
Website Tumori website
ISSN 0300-8916
OCLC 180070450
Material type Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publications in this journal

  • Tumori 09/2015; DOI:10.5301/tj.5000431
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Long non-coding RNAs (lncRNAs), a class of regulatory RNAs, play a major role in various cellular processes. Long intergenic non-coding RNAs (lincRNAs), a subclass of lncRNAs, are involved in the trans- and cis-regulation of gene expression. In the case of cis-regulation, by recruiting chromatin-modifying complexes, lincRNAs influence adjacent gene expression. Methods: We used quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR) to evaluate the coexpression of LOC100287225, a lincRNA, and DCC, one of its adjacent genes that is often decreased in colorectal cancer, in pairs of tumor and adjacent tumor-free tissues of 30 colorectal cancer patients. Results: The qRT-PCR results revealed the misregulation of these genes during tumorigenesis. Their relative expression levels were significantly lower in tumor tissues than adjacent tumor-free tissues. However, the analysis found no significant correlation between reduced expression of these genes. Conclusions: Our study demonstrated the concurrent misregulation of DCC and LOC100287225 in colorectal cancer.
    Tumori 09/2015; DOI:10.5301/tj.5000426
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aims and background: Improving survival has been documented for oral squamous cell carcinoma in recent years. It is a common malignancy in Pakistan but survival outcomes have not been reported. The objective of this study was to determine survival and identify independent predictors in patients with oral squamous cell cancer in 2 different time periods. Methods: A retrospective review of patients who received treatment between 2003 and 2012 was performed. Patients were divided into two 5 year groups: group 1 (2003-2007) (n = 628) and group 2 (2008-2012) (n = 920). Demographics, risk factors, treatment approaches, and outcomes were compared. Disease-free and overall survival were calculated. Cox proportional hazard model was used to determine independent predictors of survival. Results: A significant difference was present for ethnicity and grade and clinical T and N stage of tumors, with earlier presentation in group 2. More patients underwent surgery (p = 0.001) and had radical treatment intent (plt;0.0001) in recent years. Induction chemotherapy (p <0.0001) and palliative chemotherapy (p < 0.0001) were used more frequently. No significant difference in disease-free survival was observed but overall 5-year survival improved significantly (23% vs 42%) (p < 0.0001). Use of palliative chemotherapy reduced risk of death significantly (hazard ratio [HR] 0.1, confidence interval [CI] 0.02-0.4, p = 0.003), while pathologic nodal positivity significantly increased the risk (HR 2.5, CI 1-5.9, p = 0.03). Conclusions: These results from a single cancer hospital demonstrate improvement in overall survival secondary to early detection, better patient selection, and use of palliative chemotherapy in the later period.
    Tumori 09/2015; DOI:10.5301/tj.5000425
  • Tumori 09/2015; DOI:10.5301/tj.5000427
  • Tumori 09/2015; DOI:10.5301/tj.5000396
  • [Show abstract] [Hide abstract]
    ABSTRACT: Renal cell carcinoma (RCC) is responsible for 4% of all neoplasms in adults and for 80% of all primary renal tumors. Metastatic RCC is resistant to all cytotoxic agents and generally prognosis is poor. However, the clinical behavior of RCC is unpredictable, and late recurrences of disease can occur even after several years from the initial surgical approach, so response to the currently available targeted agents is uncertain, due to the lack of reliable prognostic and predictive factors. We report the case of a patient who developed a metastatic recurrence of RCC 16 years after primary treatment, in spite of metastatic disease at diagnosis. At the time of relapse, the disease showed a surprisingly long-term response to Sunitinib, which is maintained after 74 months of treatment. This case report highlights the unpredictable behavior of RCC and underlines the presence of a subset of patients with metastatic RCC achieving long-term response to Sunitinib, despite poor clinical features. In this subset of patients, an important clinical question arises about the appropriate duration of treatment and the need to continue it indefinitely.
    Tumori 09/2015; 101(3):0-0. DOI:10.5301/tj.5000268
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aim: The aim of the study was to look for prognostic factors of metastasis or recurrence in patients with endometrial cancer. Methods: Tumor-associated trypsin inhibitor (TATI) concentrations were measured in serum of 317 patients with endometrial cancer. The assay was done 7 times in each patient, from the moment of diagnosis until the start of follow-up after the completion of treatment. Observation of patients after treatment lasted from 0 to 16 years. Results: The TATI levels in patients with adverse prognostic factors accumulated in the first 3 assays and then decreased to zero. Mean TATI concentrations were significantly higher in patients with clinically advanced disease (stage IIIB) than patients at stage I (Kruskal-Wallis p = 0.0446). An increase in the concentration by more than 10.6% in the first 3 assays was significantly correlated with disease relapse (Mann-Whitney Z = -6.06653, p = 0.00000) and local or distant recurrence (Mann-Whitney Z = -4.97475, p = 0.000001). A significant increase in the TATI level in the first 3 tests also occurred in patients who died during the study period (Kruskal Wallis p<0.001). In our series of patients with endometrial cancer, TATI proved to be a sensitive indicator of disease recurrence and distant metastasis, with a sensitivity of 84.4% and 75.7%, respectively. Conclusions: TATI seems to behave as a prognostic factor in certain subgroups of patients with endometrial cancer.
    Tumori 08/2015; DOI:10.5301/tj.5000412
  • Tumori 07/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: The aim of this study was to investigate the important role of pathway crosstalk and pathway dysfunction in the high-metastasis process of lung cancer cells, by using the microarray expression profiles of lung cancer cells at different metastasis levels. Methods: The gene expression profile GSE10096 was downloaded from the Gene Expression Omnibus database, including 4 nonmetastasis samples, 3 low-metastasis samples (M1) and 3 high-metastasis samples (M5) of lung cancer cells. After the conversion from probe level to expression values using Jetset, the data were identified by limma package in R language to screen differentially expressed genes (DEGs). The pathways of DEGs were further enriched by the Kyoto Encyclopedia of Genes and Genomes (KEGG). A protein-protein interaction (PPI) network of genes related to the core pathway (pathway in cancer) and its neighbor pathways was constructed. Based on the PPI network, significantly changed pathway crosstalk and pathways were analyzed. Results: Compared with those in the M1 lung cancer cells, the pathways hsa00564 (glycerophospholipid metabolism) and hsa0098 (metabolism of xenobiotics by cytochrome P450) of the M5 lung cancer cells showed significant functional changes. The dysfunction of pathway crosstalk mainly occurred between pathways hsa0098 and hsa04916 (melanogenesis pathway) and other pathways. Conclusions: The results of our analysis indicate the significance of pathway crosstalk dysfunction and pathway dysfunction of M1 and M5 lung cancer cells as shown by bioinformatics methods. The present findings have the potential to lead to the study of the mechanisms of lung cancer in future.
    Tumori 06/2015; DOI:10.5301/tj.5000292
  • [Show abstract] [Hide abstract]
    ABSTRACT: Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer mortality. MicroRNAs (miRNAs), small noncoding RNAs, regulate the expression of genes that play roles in human cancer via posttranscriptional inhibition. To identify the potential miRNA biomarkers in NSCLC, we downloaded the miRNA expression profile (ID: GSE29248) of NSCLC from the Gene Expression Omnibus (GEO) database and analyzed the differentially expressed miRNAs in NSCLC tissue compared with normal control tissue. Then the targets of these differentially expressed miRNAs were screened and used in network construction and functional enrichment analysis. We identified a total of 17 miRNAs that showed a significantly differential expression in NSCLC tissue. We found that miR-34b and miR-520h might play important roles in the regulation of NSCLC, miR-22 might be a novel biomarker as an oncogene, and miR-448 might promote, while miR-654-3p prevents, NSCLC progression. Our study may provide the groundwork for further clinical molecular target therapy experiments in NSCLC.
    Tumori 05/2015; DOI:10.5301/tj.5000224
  • [Show abstract] [Hide abstract]
    ABSTRACT: AIM: This study evaluated the knowledge and attitudes of Italian mothers - whose daughters had been vaccinated in 2012 - towards primary (anti-HPV vaccination) and secondary (Pap test screening) cervical cancer prevention, as well as sources of information and mother-daughter communication on health issues. METHODS: The survey - part of a multicenter study carried out in 4 Italian cities (Ferrara, Rome, Cassino and Palermo) - was conducted through self-administered questionnaires. The first univariate analysis evaluated differences between mothers of under-18s and over-18s relative to knowledge and attitudes on HPV vaccination and Pap test. The second univariate analysis evaluated differences between the 2 groups of mothers and possible geographical variations regarding the sources of information on HPV and Pap test. RESULTS: The sample proved knowledgeable about the correlation between HPV and cervical cancer (>85%) but less aware of other HPV-related diseases. HPV vaccination should be administered before first sexual intercourse according to mothers of over-18s, and to 14- to 17-year-olds according to mothers of under-18s. Up to 88% of mothers of under-18s and 80% of mothers of over-18s declared that the vaccine should be given free of charge. More mothers of under-18s consulted a general practitioner (GP) or gynecologist before deciding to vaccinate their daughters. Mothers of under-18s received information on HPV vaccination mainly from GPs and gynecologists, while mothers of over-18s were informed through TV and books/journals. Over 80% of the sample declared satisfaction with the information received from their gynecologist during the Pap test. CONCLUSIONS: The findings provide useful information for the development of effective public health interventions that may help improve acceptance of HPV vaccination among mothers.
    Tumori 04/2015; 3(3). DOI:10.5301/tj.5000293
  • Tumori 03/2015; DOI:10.5301/tj.5000295
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatocellular carcinoma (HCC) is a dismal malignancy associated with multiple molecular changes. The purpose of this study was to identify the differentially expressed genes and analyze the biological processes related to HCC. Datasets of HCC were obtained from the NCBI Gene Expression Omnibus. Integrated analysis of differentially expressed genes was performed using the INMEX program. Then Gene Ontology enrichment analyses and pathway analysis were performed based on the Gene Ontology website and Kyoto Encyclopedia of Genes and Genomes. A protein-protein interaction network was constructed using the Cytoscape software; the netwerk served to find hub genes for HCC. Real-time RT-PCR was used to validate the microarray data for hub genes. We identified 273 genes that were differentially expressed in HCC. Gene Ontology enrichment analyses revealed response to cadmium ion, cellular response to cadmium ion, and cellular response to zinc ion for these genes. Pathway analysis showed that significant pathways included fatty acid metabolism, butanoate metabolism, and PPAR signaling pathway. The protein-protein interaction network indicated that CDH1, ECHS1, ACAA1, MT2A, and MYC were important genes which participated in many interactions. Experimental validation of the role of four upregulated genes (ECHS1, ACAA1, MT2A and MYC) in the progression of HCC was carried out. Our study displayed genes that were consistently differentially expressed in HCC. The biological pathways and protein-protein interaction networks associated with those genes were also identified. We predicted that CDH1, ECHS1, ACAA1, MT2A, and MYC might be target genes for diagnosing HCC.
    Tumori 03/2015; DOI:10.5301/tj.5000241
  • [Show abstract] [Hide abstract]
    ABSTRACT: Thoracic surgery for a newly diagnosed primary lung tumor following a previous pneumonectomy is rarely indicated. Stereotactic ablative radiotherapy (SABR) might represent a curative option. This report focuses on outcomes, toxicity and quality of life (QoL) after SABR. Nine patients were treated with SABR between 2004 and 2011; median time since surgery was 8.4 years. In 4 cases, a histological confirmation was possible with bronchoscopy. In 5 cases, the clinical proof of malignancy was based on radiological criteria. Forced expiratory volume in 1 second (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) were tested in all patients. A SABR biologically equivalent dose of >100 Gy was prescribed in all cases. QoL questionnaire forms were administered before SABR and during follow-up. Median follow-up was 41.8 months. We did not observe grade ≥3 acute toxicity, and concerning late toxicity, we registered 2 cases. QoL was decreased during the first 12 months of follow-up, followed by a progressive improvement after this time. One patient had a local relapse at 7.4 years; 1 developed a new nodule at 5.5 years, associated with metastases; and 1 developed a new nodule without any systemic disease at 3 years. There were 2 cancer-related deaths (18.2%) at 3 and 12 months after progression. Data support efficacy and safety of SABR in patients with a new primary lung cancer following previous pneumonectomy, with acceptable acute, late toxicity profile and without significant impairment of QoL. Our results were comparable to those in the literature.
    Tumori 03/2015; DOI:10.5301/tj.5000227